Knowledge Management System of Hefei Institute of Physical Science,CAS
Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study | |
Shao, Xiying1,2; Zheng, Yabing1,2; Cao, Wenming1,2; Shen, Xiabo1,2; Li, Guangliang1,2; Chen, Junqing1,2; Huang, Yuan1,2; Huang, Ping1,2; Shi, Lei1,2; Ye, Weiwu1,2; Zou, Weibin1,2; Lou, Caijin1,2; Lei, Lei1,2; Huang, Jian1,2; Chen, Zhanhong1,2; Wang, Xiaojia1,2 | |
2021-04-01 | |
发表期刊 | ANNALS OF TRANSLATIONAL MEDICINE |
ISSN | 2305-5839 |
通讯作者 | Chen, Zhanhong(czred@sina.com) ; Wang, Xiaojia(wxiaojia0803@163.com) |
摘要 | Background: Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). A key challenge remains to uncover biomarkers to identify those patients who may benefit from palbociclib treatment. Methods: We retrospectively analyzed the values of Ki67 and progesterone receptor (PR) as detected by immunohistochemistry in 81 ABC patients with palbociclib and hormone therapy treatment, and evaluated the impact on progression-free survival (PFS). Results: In the total population, women with Ki67 >= 14% had marginally significantly shorter PFS than those with Ki67 <14% (P=0.062). Patients with Ki67 >= 30% had significantly shorter PFS than those with Ki67 <30% (P=0.048). Meanwhile, PR >= 20% was associated with longer PFS. Moreover, the change of Ki67 or PR from primary tissue to metastatic lesions was related to PFS. As for the hormone therapy subgroup, there were significant associations between Ki67 and PR levels and PFS in the aromatase inhibitors (AIs) subgroup. Patients with Ki67 >= 14% or Ki67 >= 30% had shorter PFS than those with Ki67 < 14% or Ki67 < 30%, respectively (P=0.024, P<0.001). Additionally, the change of Ki67 or PR from primary tissue to metastatic lesions was related to PFS. When both Ki67 and PR were considered, there were significant differences between the different cohorts. Compared with patients with Ki67 >= 14% and PR <20%, those with Ki67 <14% and PR >= 20% had significantly longer PFS. In addition, patients with Ki67 <30% and PR >= 20% had significantly longer PFS than those with Ki67 >= 30% and PR <20%. Furthermore, in the AI cohort, patients with Ki67 <14% and PR >= 20% had significantly longer PFS than those with Ki67 >= 14% and PR <20%. Women with Ki67 <30% and PR >= 20% had significantly longer PFS than those with Ki67 >= 30% and PR <20%. Conclusions: The present study indicates that both Ki67 and PR have great impacts on palbociclib and hormone therapy and may contribute to selecting more effective partners for palbociclib. |
关键词 | Ki67 progesterone receptor palbociclib |
DOI | 10.21037/atm-21-1340 |
关键词[WOS] | ADVANCED BREAST-CANCER ; KINASE 4/6 INHIBITOR ; ESTROGEN-RECEPTOR ; ENDOCRINE THERAPY ; POTENTIAL BIOMARKERS ; CDK4/6 INHIBITORS ; FULVESTRANT ; COMBINATION ; RESISTANCE ; ABEMACICLIB |
收录类别 | SCI |
语种 | 英语 |
资助项目 | Zhejiang Provincial Natural Science Foundation[Y2101312] ; Zhejiang Provincial Natural Science Foundation[LY17H160041] ; Zhejiang Provincial Medical Science and Technology Program[2010QNA006] ; Zhejiang Provincial Medical Science and Technology Program[2021KY551] ; Zhejiang science and Technology Program[2016C33199] ; Special Fund of Wu Jieping Medical Foundation Clinical Research[320.670010007] |
项目资助者 | Zhejiang Provincial Natural Science Foundation ; Zhejiang Provincial Medical Science and Technology Program ; Zhejiang science and Technology Program ; Special Fund of Wu Jieping Medical Foundation Clinical Research |
WOS研究方向 | Oncology ; Research & Experimental Medicine |
WOS类目 | Oncology ; Medicine, Research & Experimental |
WOS记录号 | WOS:000647719800002 |
出版者 | AME PUBL CO |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/122352 |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Chen, Zhanhong; Wang, Xiaojia |
作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou, Peoples R China |
推荐引用方式 GB/T 7714 | Shao, Xiying,Zheng, Yabing,Cao, Wenming,et al. Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study[J]. ANNALS OF TRANSLATIONAL MEDICINE,2021,9. |
APA | Shao, Xiying.,Zheng, Yabing.,Cao, Wenming.,Shen, Xiabo.,Li, Guangliang.,...&Wang, Xiaojia.(2021).Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study.ANNALS OF TRANSLATIONAL MEDICINE,9. |
MLA | Shao, Xiying,et al."Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study".ANNALS OF TRANSLATIONAL MEDICINE 9(2021). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论